Arctic Vision

Arctic Vision

Private
Shanghai, ShanghaiHealthcare & Life Scienceshttps://www.arcticvision.com

Last Round

Series B

Mar 9, 2021

Total Funding Raised

$132M

Company Overview

Arctic Vision is a biotechnology company focused on ophthalmology, developing innovative gene therapies to meet the unmet clinical treatment needs of patients with rare ophthalmic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Medical Devices, Precision Medicine

Business Model

B2B2C

Customer Profile

Hardware Sales, Hardware + Subscription, Data as a Service

AI Layer

Non-AI

Keywords

ophthalmology therapieseye care biotechbiotech in-licensingclinical stage biotechocular drug deliverysuprachoroidal injectionuveitic macular edemaophthalmic gene therapyneurostimulation devicedry eye diseaseophthalmic cell therapyintraocular lensesIOLspresbyopia treatmentpresbyopia dropsmyopia controlpediatric myopiaconsumer eye care

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Arctic Vision Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Arctic Vision Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BMar 9, 2021
Series AJul 13, 2020
SeedMay 1, 2019

Key People

Founding team and executive leadership

Qing Liu

Chief Medical Officer, Co-founder

Founding Team

Eddy Wu

Founder, Chairman CEO

Founding Team

Arctic Vision Investors

Notable investors and investment history

InvestorRounds
Loyal Valley CapitalSeries B
Morningside VenturesSeries B, Series A
Nan Fung Life SciencesSeries B, Series A, Seed
Nan Fung GroupSeries B, Series A
Octagon CapitalSeries B
Pivotal bioVenture Partners ChinaSeries B, Series A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 17, 2025

    Attended Hurun Global Gazelles 2024 and received an award.

  • Jan 17, 2025

    Won the Hurun Global Gazelles 2024 award.

Arctic Vision Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Arctic Vision Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Arctic Vision's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai, Shanghai
Employee Range27
Year Founded2019
Last FundingMar 9, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.